Health News
Taxotere won the approval for head and neck cancer
U.S. Food and Drug Administration (FDA) has approved Taxotere (Docetaxel) injection concentrate in combination with Cisplatin and 5-Fluorouracil (TPF regimen) for induction therapy of locally advanced squamous cell carcinoma of head and neck before patients undergo surgery and chemo-radiotherapy, says a recent press release.
The FDA based its approval on the results of the phase III randomised, open-label, international trial, TAX324, which established the efficacy and safety of the Taxotere-based regimen in significantly improving survival.
"Head and neck cancer is particularly hard to treat and if not detected early has now survival rates" commented Nancy Leupold, survivor, President and Founder of Support for People with Oral and Head and Neck Cancer.
Taxotere is a drug of Sanofi Aventis Ltd.
For all latest news, follow The Daily Star's Google News channel.
Comments